Resveratrol: the "red wine longevity compound," tracked in real people for 9 years

Human evidence: D (no confirmed link with clinical outcomes) Updated: October 2026

Summary: Resveratrol is the flagship of "anti-aging" supplements, but no link with clinical outcomes (death, disease incidence) has been confirmed in humans. Meta-analyses of small RCTs show small improvements in intermediate markers (inflammation, blood pressure, insulin resistance) — but the trials stop at surrogate endpoints. We treat it as a D-rated example.

What is claimed

Resveratrol is a polyphenol in grape skins and red wine, popularized in the 1990s as a proposed explanation for the "French paradox." Animal studies reported SIRT1 activation, lifespan extension, and reduced atherosclerosis, making it the poster compound of the anti-aging supplement market.

What has actually been shown

1. Cohort: no association with death or disease (InCHIANTI, 2014)

The direct test — do people who actually consume more resveratrol live longer? In the Italian InCHIANTI study, urinary resveratrol metabolites were measured in 783 adults aged 65+ and followed ~9 years (268 deaths): no significant association with all-cause mortality, cardiovascular mortality, inflammation markers, cardiovascular disease, or cancer (p=0.67). As an explanation of the French paradox, this cohort did not support it.

2. Meta-analyses: small improvements in intermediate markers, clinical endpoints blank

A 2022 meta-analysis of 6 RCTs found significant reductions in inflammatory markers: CRP mean difference −0.63, TNF-α −0.55 (IL-6 null). A 2024 meta-analysis confirmed TNF-α reduction with high certainty in primary-prevention groups. A 2025 meta-analysis found small improvements in HOMA-IR, total and LDL cholesterol, blood pressure, and inflammatory markers — but no effect on fasting glucose, HbA1c, body composition, liver enzymes, or HDL.

Surrogate markers are not clinical outcomes. A 0.6 drop in CRP is not evidence of fewer heart attacks. Nearly all resveratrol trials stop at intermediate markers, and the one study that measured real outcomes (the cohort above) was null.

3. Bioavailability is extremely low

Oral resveratrol is metabolized rapidly; human plasma levels stay below the micromolar range. Lifespan-extension doses in mice are tens to hundreds of times higher than what a human capsule can reach. This is the main reason "longevity in mice" has not translated to "supplement in humans."

Weaknesses & cautions

Most efficacy RCTs have 10–15 participants; even meta-analyzed, totals remain in the hundreds.
Possible interactions with anticoagulants (warfarin) have been flagged.
"Drinking more red wine" carries alcohol risk — the compound and the beverage are separate evaluations.

Bottom line

Resveratrol is the textbook pattern of the anti-aging supplement industry: promising in animals → small improvements in intermediate markers → no association with real outcomes. Enjoying red wine as part of a diet is a separate question; as an anti-aging capsule it is rated D.

Sources

Bazzano LA et al. Resveratrol intake and markers of cardiovascular disease risk and inflammation: InCHIANTI cohort. JAMA Intern Med 174(7):1132–1139 (2014). PMID 24819981
Mousavi SM et al. Resveratrol and cardiovascular disease risk factors: a systematic review and meta-analysis of RCTs. Arch Med Res (2022). PMID 35905799
Shiwan Y et al. Effect of resveratrol on inflammatory biomarkers: a meta-analysis of RCTs. Rheumatol Int 44 (2024). Springer
Meta-analysis of resveratrol on cardiometabolic outcomes (2025). PMC12949888

Informational content only — not medical advice. Consult a clinician if you have a medical condition or take medications.